TITLE

Etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment

PUB. DATE
March 2005
SOURCE
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p44
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a study which states that etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment. The study was published in the 2004 issue of the journal "Thorax." The study included 352 men and women 50 to 70 years of age who were outpatients. Patients had asthma and had been taking regular oral or inhaled glucocorticoids, or both, for a period of one year. The conclusion of the study was that in patients with asthma receiving long-term glucocorticoid treatment, etidronate and calcium used alone or combined did not reduce fracture rates.
ACCESSION #
16486589

 

Related Articles

  • A Comparison of Continuous Alendronate, Cyclical Alendronate and Cyclical Etidronate with Calcitriol in the Treatment of Postmenopausal Vertebral Osteoporosis: A Randomized Controlled Trial. Sahota, O.; Fowler, I.; Blackwell, P. J.; Lawson, N.; Cawte, S. A.; San, P.; Masud, T.; Hosking, D. J. // Osteoporosis International;Nov2000, Vol. 11 Issue 11, p959 

    : A number of drugs are now available for the treatment of established osteoporosis and have been shown to significantly increase bone mineral density (BMD). There are, however, few comparative treatment studies and, furthermore, adverse events remain a problem with some of the newer agents,...

  • Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts. Shu, Goukei; Yamamoto, Kaname; Nagashima, Masakazu // Modern Rheumatology (Springer Science & Business Media B.V.);Dec2006, Vol. 16 Issue 6, p343 

    Patients with rheumatoid arthritis commonly suffer both systemic and periarticular osteoporosis. Bisphosphonates (BPs) are inhibitors of bone resorption, and several derivatives have been developed for treatment of enhanced bone resorption. We aimed to characterize osteoclast formation in two...

  • Early Initiation of Bisphosphonate Does Not Affect Healing and Outcomes of Volar Plate Fixation of Osteoporotic Distal Radial Fractures. Hyun Sik Gong; Cheol Ho Song; Young Ho Lee; Seung Hwan Rhee; Hyuk Jin Lee; Goo Hyun Baek // Journal of Bone & Joint Surgery, American Volume;10/3/2012, Vol. 94-A Issue 19, p1729 

    Background: Bisphosphonates can adversely affect fracture-healing because they inhibit osteoclastic bone resorption. It is unclear whether bisphosphonates can be initiated safely for patients who have sustained an acute distal radial fracture. The purpose of this randomized study was to...

  • COMMENTARY: Etidronate, calcium, or both did not reduce fracture rates in patients with asthma receiving glucocorticoid treatment. Jamal, Sophie A. // ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p44 

    The article comments on a study which examines the effects of etidronate, calcium, or placebo on bone mineral density (BMD) and fractures in patients taking oral or inhaled glucocorticoids or both for asthma. Patients randomized to etidronate had a 5% increase in lumbar spine BMD. No difference...

  • Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy. Mori, Hiroko; Okada, Yosuke; Yamaoka, Kunihiro; Saito, Kazuyoshi; Tanaka, Yoshiya // Journal of Bone & Mineral Metabolism;Jan2012, Vol. 30 Issue 1, p114 

    We report a 26-year-old woman with severe calcinosis associated with dermatomyositis. Although calcinosis of the skin or muscles is unusual in adults with dermatomyositis, this patient developed subcutaneous calcinosis with tenderness on the arms, axillary areas, shoulder areas, chest, abdomen,...

  • etidronate.  // Davis's Drug Guide for Nurses, 10th edition;2007, p493 

    The article presents a nursing guide to etidronate, a drug used for the treatment of Paget's disease of bone and prophylaxis of heterotopic calcification, among others. Its mechanism of action and pharmacokinetics are explained. Contraindications for the drug are presented. Its adverse reactions...

  • Didronel.  // Royal Society of Medicine: Medicines;2002, p201 

    This article presents information on Didronel, a proprietary, prescription-only preparation of disodium etidronate. It can be used to reduce the rate of bone turnover in treating the condition known as Paget's disease of the bone. It is available as tablets.

  • Didronel PMO.  // Royal Society of Medicine: Medicines;2002, p201 

    The article presents information on Didronel PMO, a proprietary, prescription-only compound preparation of the calcium metabolism modifier disodium etidronate and calcium carbonate. It can be used in the prevention and treatment of osteoporosis, in postmenopausal women, and prevention and...

  • pamidronate.  // Davis's Drug Guide for Nurses, 10th edition;2007, p914 

    This article presents information on the drug pamidronate, which is marketed as Aredia. It is classified as bone resorption inhibitor and pharmacologically it falls under biphosphonates and hypocalcemics. It is used to treat moderate to severe hypercalcemia associated with malignancy....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics